Last updated 10 days ago

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

600 patients around the world
Available in Chile, United States
Merck Sharp & Dohme LLC
2Research sites
600Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto Oncológico FALP - UIDO
Recruiting
José Manuel Infante 805, Providencia, Región Metropolitana
Centro de Oncología de Precisión
Recruiting
Santiago, Región Metropolitana de Santiago, 7560908
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy